Clinical trial
On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection
NCT02376478 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection
- Lead sponsor
- Medical University of Vienna
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 31, 2009
- Completion date
- January 31, 2011
- Enrollment
- 222 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.